25 results
8-K
EX-99.1
ANVS
Annovis Bio Inc
13 May 24
Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results
4:05pm
months ended March 31, 2024 was $6.7 million, which included a $6.7 million non-cash gain from change in fair value of liability-classified warrants
UPLOAD
ANVS
Annovis Bio Inc
21 Jun 19
Letter from SEC
12:00am
of
cause unless the board is classified or the directors are elected via
cumulative voting.
Refer to Frechter v. Zier, C.A. No. 12038
CORRESP
ANVS
Annovis Bio Inc
2 Jul 19
Correspondence with SEC
12:00am
of directors by shareholders to cases of cause unless the board is classified or the directors are elected via cumulative voting. Refer to Frechter v
424B5
ANVS
Annovis Bio Inc
1 Nov 23
Prospectus supplement for primary offering
12:24pm
is incorporated by reference in this prospectus supplement, there were material amounts inappropriately classified as research and development expense … which should have been classified as prepaid assets and other assets. We are taking steps to remediate the material weakness and are in the process
424B5
w40dbd8abqh76vj
30 Oct 23
Prospectus supplement for primary offering
5:27pm
424B5
uga92slf b936ktr6
18 Mar 24
Prospectus supplement for primary offering
8:51pm
424B5
4k3lsrx4c4d
18 Mar 24
Prospectus supplement for primary offering
10:00pm
S-1
1b8bxxxkevkto94sl
2 Jul 19
IPO registration
9:15pm
8-K
EX-10.2
s9lw lzd5
15 Mar 24
Entry into a Material Definitive Agreement
5:22pm
8-K
EX-10.2
vyczf3cxbtmw
21 Mar 24
Entry into a Material Definitive Agreement
5:23pm
424B4
huqfuq0cgjp56zsfsl
30 Jan 20
Prospectus supplement with pricing info
6:07am